Precision Medicine. Inspired by Hope.

INNOVOTEX is redefining cancer treatment with a clinically de-risked drug delivery platform that precisely targets aggressive, treatment-resistant tumors.

Our Mission

Pioneering macrocycle drug conjugates

Our Macrocycle Drug Conjugates (MDCs) target aggressive, treatment-resistant tumors using clinically validated delivery systems.

Our lead candidate, NOVO-111, has shown remarkable preclinical results and is on track for clinical trials.

SCIENCE

Transforming the Treatment Paradigm

Clinical Validation

Increased Versatility

Platform leverages a clinically validated macrocycle used in >1000 patients.

Increased Versatility

Tumor localizing macrocycle core capable of carrying multi-modal payloads.

Market Expansion

Increased Versatility

Market Expansion

Optionality across multiple market indications resulting in new IP.

Latest News

INNOVOTEX to present Breakthrough Data at the American Association of Cancer Research Annual Meeting!

NEWS

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept